ESR1 and cancer: Since about one-half of the patients with estrogen receptor- positive cancer fail on tamoxifen[10], [11], identification of effective and reliable biomarkers that could be used to monitor tamoxifen efficacy and new targets to reverse tamoxifen resistance is of crucial importance.